RADNOR, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Zeta Global Holdings Corp. (NYSE: ZETA) (“Zeta”).
On November 13, 2024, Culper Research published a report alleging that Zeta has been engaging in deceptive data collection practices. Specifically, the report alleged that “Zeta has quietly spun up its own network of consent farms i.e., sham websites that hoodwink millions of consumers each month into handing their data over to Zeta under false pretenses, baited by job applications, stimulus money, or other rewards that simply do not exist.”
On this news, Zeta’s common stock price fell $10.48 per share, or 37.14%, to close at $17.74 per share on November 13, 2024.
If you are a Zeta investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://www.ktmc.com/zeta-global-holdings-corp-investigation?utm_source=PR&utm_medium=link&utm_campaign=zeta&mktm=r
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma - December 8, 2024
- Slate360 Provides Valuable Insights on the Advantages of Working with a Skilled Healthcare Event Marketing Agency - December 8, 2024
- Global Aerospace’s SM4 Aviation Safety Program Provides Actionable Advice for Enhancing Safety in Your Flight Department - December 8, 2024